Health TrialsbyHealthPanel

Relapsed/Refractory Large B-cell Lymphoma (LBCL)

2

Review clinical trials related to Relapsed/Refractory Large B-cell Lymphoma (LBCL). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate (CR rate) between the experimental cohort and the historical control cohort (NCT04833504).

Participants needed: 70
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital, Zhejiang University, School of MedicineUpdated: Aug 26, 2026Locations: 1
Eligibility criteria

Voluntarily participate in this study and sign the informed consent form. [+11]

History of other malignant tumors (excluding cured basal cell carcinoma, cervica... [+8]

Read more
Status: Not yet recruiting

Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cell therapy with or without rimegepant. The primary endpoint is complete response rate at 6 months after CAR-T cell infusion.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: May 29, 2026Locations: 1
Eligibility criteria

Able to understand and voluntarily sign the written informed consent form. [+11]

History of hypersensitivity to any study treatment or related compounds. [+14]

Read more